Brief: Timber Pharmaceuticals Inc - Expects To Initiate A Phase 3 Clinical Trial For TMB-001 In Q2 Of 2022

Trex Wind-Down

25/04/2022 22:24

April 25 (Reuters) - Timber Pharmaceuticals Inc  TMBR.A :
    * TIMBER PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 3
CLINICAL TRIAL FOR TMB-001 IN Q2 OF 2022
    * TIMBER PHARMACEUTICALS INC - HAS COMPLETED ITS STRATEGIC
EVALUATION AND WILL BE PRIORITIZING ADVANCEMENT OF ITS LEAD
PRODUCT CANDIDATE TMB-001

Source text for Eikon:  ID: 
Further company coverage:  TMBR.A 

 ((Reuters.Briefs@thomsonreuters.com;))